Perspective · 14 Jun 2023
Conference abstractPublished 24 Aug 2015
Engineering customized anti-tumor immune response: Biology of MHC class I restricted TCR engineered CD4 T cells
University of Connecticut Health Center, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
TCR engineered anti-tumor T cells have produced remarkable responses in cancer patients, however, generation of customized anti-tumor T cells with predefined functional characteristics remains a challenge. We are working on characterizing the biology of tumor antigen specific TCR engineered T cells, to develop methodologies for generating T cells with predefined functional profiles. We have recently shown that TCR engineering approach can also be utilized to program human CD4 T cells to function as MHC class I restricted anti-tumor effectors that can simultaneously exhibit a helper response as well as cytolytic effector response (Chhabra et al., JI, 2008 and Ray et al., J. Clin. Immunol., 2010). Interestingly, we have found that these MHC class I restricted multifunctional CD4 T cells can also mitigate regulatory T cell (Treg) mediated immune suppression. Furthermore, we have found that these engineered CD4 T cells are also susceptible to epitope specific activation induced cell death (AICD), that has distinct differences from AICD in TCR engineered CD8 T cells (Chhabra et al., JI, 2013). We will share our recent findings on biology of MHC class I restricted CD4 T cells, such as their effector function profile, ability to mitigate Treg-mediated immune suppression, and their susceptibility to undergo AICD. We will also discuss molecular pathways involved in development of multifunctional effector profile of MHC class I restricted CD4 T cells, and strategies for generating customized anti-tumor T cells with predefined functional profiles.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 2013
Engineering Anti-Tumor T Cell Immunity
Conference abstract · 20 Mar 2017
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells
Conference abstract · 11 Aug 2016
Tumor-derived CD200 Inhibits the Development of an Anti-tumor Response:Implications for Immuntherapy.
Conference abstract · 29 Sep 2014
Cross-talk between CD8+ T and NK cells: Fine-tuning of anti-tumor immune response
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectEngineering
- SubjectImmunology & Microbiology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Arvind Chhabra”
